Literature DB >> 20886544

Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance.

Georg Winterer1, Kirstin Mittelstrass, Ina Giegling, Claudia Lamina, Christoph Fehr, Hermann Brenner, Lutz P Breitling, Barbara Nitz, Elke Raum, Heiko Müller, Jürgen Gallinat, Andreas Gal, Katharina Heim, Holger Prokisch, Thomas Meitinger, Annette M Hartmann, Hans-Jürgen Möller, Christian Gieger, H-Erich Wichmann, Thomas Illig, Norbert Dahmen, Dan Rujescu.   

Abstract

Recent studies strongly support an association of the nicotinic acetylcholine receptor gene cluster CHRNA5-CHRNA3-CHRNB4 with nicotine dependence (ND). However, the precise genotype-phenotype relationship is still unknown. Clinical and epidemiological data on smoking behavior raise the possibility that the relevant gene variants may indirectly contribute to the development of ND by affecting cognitive performance in some smokers who consume nicotine for reasons of "cognition enhancement." Here, we tested seven single nucleotide polymorphisms (SNPs) rs684513, rs637137, rs16969968, rs578776, rs1051730, rs3743078, rs3813567 from the CHRNA5-CHRNA3-CHRNB4 gene cluster for association with ND, measures of cognitive performance and gene expression. As expected, we found all SNPs being associated with ND in three independent cohorts (KORA, NCOOP, ESTHER) comprising 5,561 individuals. In an overlapping sample of 2,186 subjects we found three SNPs (rs16969968, rs1051730, rs3743078) being associated with cognitive domains from the Wechsler-Adult-Intelligence Scale (WAIS-R)-most notably in the performance subtest "object assembly" and the verbal subtest "similarities." In a refined analysis of a subsample of 485 subjects, two of these three SNPs (rs16969968, rs1051730) were associated with n-back task performance/Continuous Performance Test. Furthermore, two CHRNA5 risk alleles (rs684513, rs637137) were associated with CHRNA5 mRNA expression levels in whole blood in a subgroup of 190 subjects. We here report for the first time an association of CHRNA5-CHRNA3-CHRNB4 gene variants with cognition possibly mediating in part risk for developing ND. The observed phenotype-genotype associations may depend on altered levels of gene expression. © 2010 Wiley-Liss, Inc.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886544     DOI: 10.1002/ajmg.b.31126

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  32 in total

Review 1.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

Review 2.  Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective.

Authors:  Boris B Quednow; Magdalena M Brzózka; Moritz J Rossner
Journal:  Cell Mol Life Sci       Date:  2014-01-12       Impact factor: 9.261

3.  Nicotinic α5 subunits drive developmental changes in the activation and morphology of prefrontal cortex layer VI neurons.

Authors:  Craig D C Bailey; Nyresa C Alves; Raad Nashmi; Mariella De Biasi; Evelyn K Lambe
Journal:  Biol Psychiatry       Date:  2011-10-25       Impact factor: 13.382

4.  Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women.

Authors:  Amy C Janes; Jordan W Smoller; Sean P David; Blaise Deb Frederick; Stephen Haddad; Aditi Basu; Maurizio Fava; A Eden Evins; Marc J Kaufman
Journal:  Drug Alcohol Depend       Date:  2011-07-20       Impact factor: 4.492

5.  A CHRNA5 allele related to nicotine addiction and schizophrenia.

Authors:  L E Hong; X Yang; I Wonodi; C A Hodgkinson; D Goldman; O C Stine; E S Stein; G K Thaker
Journal:  Genes Brain Behav       Date:  2011-04-06       Impact factor: 3.449

6.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

7.  CHRNA5 variants moderate the effect of nicotine deprivation on a neural index of cognitive control.

Authors:  D E Evans; D A MacQueen; K G Jentink; J Y Park; H-Y Lin; D J Drobes
Journal:  Genes Brain Behav       Date:  2014-07-23       Impact factor: 3.449

8.  Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.

Authors:  Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

9.  Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.

Authors:  Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

10.  Cannabinoid receptor 1 (CNR1) gene variant moderates neural index of cognitive disruption during nicotine withdrawal.

Authors:  D E Evans; S K Sutton; K G Jentink; H-Y Lin; J Y Park; D J Drobes
Journal:  Genes Brain Behav       Date:  2016-09       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.